Global Cord Blood (NYSE:CO) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:CO) in a research note issued on Saturday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Price Performance

Shares of NYSE CO opened at $1.25 on Friday. The firm’s 50-day moving average price is $1.53 and its two-hundred day moving average price is $1.36. Global Cord Blood has a 52-week low of $2.03 and a 52-week high of $5.50. The stock has a market capitalization of $151.94 million, a P/E ratio of 1.95 and a beta of 0.16.

Institutional Investors Weigh In On Global Cord Blood

Large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp bought a new position in Global Cord Blood in the 2nd quarter worth about $96,000. Natixis Advisors L.P. grew its position in Global Cord Blood by 6.6% in the 1st quarter. Natixis Advisors L.P. now owns 189,330 shares of the medical research company’s stock valued at $729,000 after buying an additional 11,709 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC increased its stake in Global Cord Blood by 99,844.5% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock valued at $77,957,000 after buying an additional 26,067,412 shares during the period.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.